Clinical study of Moxifloxacin in the treatment of elderly patients with community acquired pneumonia
Abstract
[Objective] To evaluate the clinical efficacy and safety of Moxifloxacin in the treatment of elderly patients with community acquired pneumonia (CAP). [Methods] Elderly patients with CAP were treated with moxifloxacin or cefuroxime in a randomized controlled study. [Results] A total of 119 patients were enrolled in this study, 60 patients in Moxifloxacin group, 59 patients in Cefuroxime group. The cure rates and the effective rates of Moxifloxacin group and cefuroxime group were 50%, 39% (P 0.05) and 90%, 69% (P 0.05), respectively. The bacterial eradication rates of the two groups were 84% and 53%, respectively. The rates of adverse reaction in the two groups were 8%, 5% (P 0.05.), respectively. [Conclusion] Moxifloxacin is effective and safe for the treatment of elderly patients with CAP, which has a high clinical value.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 119 participants or records.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.